GRAIL

Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9

🎙️ It’s #NationalPodcastDay! Have you subscribed to The Cancer SIGNAL? Check out GRAIL’s podcast where experts, advocates and patients discuss the stories and science behind early cancer detection. From multi-cancer early detection (MCED) testing to cancer genomics, we are exploring the future of cancer screening from a wide variety of perspectives. Listen on Apple, Spotify, Amazon Music or wherever you get your podcasts. https://apple.co/3W0dso3

Seven in 10 Americans are behind on at least one guideline recommended cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins host Susanna Quinn on the latest episode of #TheCancerSignal podcast to discuss cancer screening behaviors and why early cancer detection is so critical for patients. Listen on Apple, Spotify, Amazon Music or wherever you get your podcasts. https://apple.co/3XuNgEo

National Hereditary Breast and Ovarian Cancer Week highlights the importance of understanding genetic factors in breast cancer and ovarian cancer. In this previous podcast episode, we spotlight recent advances in the fight against hereditary breast cancer. Krissa Smith from Susan G. Komen shares about #BRCA gene research, its impact on #BreastCancer risk, and her family’s experience with hereditary breast cancer. Listen on Apple, Spotify, Amazon Music or wherever you get your podcasts. https://apple.co/3B10W2p #HBOCWeek

A recently published study in Health Affairs explores barriers and facilitators to multi-cancer early detection (MCED) adoption in marginalized communities. Addressing psychological impacts, provider relationships, trust, and accessibility can enhance adoption and advance health equity. Read more here: https://lnkd.in/gs9nbhXB #HealthEquity #MCED #CancerScreening

Results from multi-cancer early detection (MCED) testing led doctors to conduct further testing that diagnosed Dave’s cancer early, allowing him to start treatment before it affected his lifestyle. Learn more about MCED testing: https://bit.ly/4d8o38q #BloodCancerAwarenessMonth

We brought several innovative presentations to #ESMO24, focused on advancing our understanding of how GRAIL technology can be applied in clinical trials, and the impact of multi-cancer early detection (MCED) testing. Here are the highlights from our research: 🔎 Early real-world evidence stresses the importance of persistent workups, particularly in patients with multiple positive tests (e.g., a positive test followed by a negative workup, then a positive retest), where the risk of cancer remains high and requires vigilant follow-up. 🧬 Cell-free DNA analysis reveals that cancer signals may be detectable up to 30 months before diagnosis, opening doors to earlier interventions. 📊 Participant-reported data suggest that MCED testing helps drive proactive health behaviors, especially among those identified as high risk for cancer. 💡 Economic and clinical models demonstrate the potential benefits of MCED testing for individuals with hereditary cancer syndromes, with implications for both patient outcomes and healthcare costs. 🔬Exploratory analysis suggests that measuring circulating tumor DNA (ctDNA) may help identify people with Stage 3 unresectable non-small cell lung cancer (NSCLC) who could benefit from more treatment after radiation therapy. 🩸 Clearance of ctDNA from the blood during treatment could signal improved outcomes in certain bladder cancer patients, serving as a potential marker of treatment success. Go deeper. Explore our full presentations: https://bit.ly/3XbEQlk

“Our Cuban culture is all about family, staying close together.” As we celebrate #HispanicHeritageMonth, we reflect on the cultural values that shape us. For Cindy, her strong connection to her family drove her to seek proactive cancer screening. Her story speaks to the importance of prioritizing your health and having a strong family support system. https://bit.ly/44RHQVD

At #ESMO24, GRAIL will be presenting a variety of data centered on enhancing our knowledge of multi-cancer early detection (MCED) testing, as well as on use of GRAIL technology in pharma research applications. Visit us at our posters and presentations! Interested in meeting and learning more about biopharma partnership opportunities? Reach out at PharmaBD@grailbio.com

For firefighters, the battle doesn’t end when the fire is out. Health risks such as cancer are a constant concern, but new tools may be able to help. The Chicago Fire Department shares how tools like multi-cancer early detection (MCED) testing are helping them stay ahead of these unseen dangers. Learn more: https://bit.ly/47vdew3 #MCED #CancerScreening